Trial Profile
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Alirinetide (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms GALS
- Sponsors Genervon Biopharmaceuticals
- 08 Dec 2017 According to a Genervon Biopharmaceuticals media release, data from this trial will be presented at the 28th national symposium on ALS/MND (Dec 2017).
- 22 Sep 2015 Results published in the Media Release.
- 28 Apr 2014 Preliminary data reported in a Genervon Biopharmaceuticals media release.